Mr. Yu Hai joined the Group in February 2023 as an executive Director and the Chief Executive Officer, and was appointed as the Chairman of the board and the chairman of the Nomination Committee in June 2025. He is currently the chairman of China Resources Healthcare Group Limited which is an indirect controlling shareholder of the Company. Mr. YU served as the vice-chairman, the general manager and the senior vice general manager of CR Healthcare from January 2020 to June 2025 and as the chairman of Liaoning Healthcare Industry Group Co., Ltd. from July 2018 to January 2020. Mr. YU worked in Benxi Municipal Government, Liaoning Province from July 2008 to July 2018, and served as the deputy mayor of Benxi City etc. Prior to that, Mr. YU held various positions at government departments including the deputy director of the Social Development Division of the Department of Science & Technology of Liaoning Province, the deputy director of the High-tech Development and Industrialization Division of the Department of Science & Technology of Liaoning Province, the deputy director of the Bureau of Science and Technology of Nagchu District, the Tibet Autonomous Region, and the principal officer of the Industrial and Social Development Division, the Scientific and Technological Commission of Liaoning Province etc.. Mr. YU holds a doctor of science degree in pharmaceutical affairs management from the School of Pharmacy, Shenyang Pharmaceutical University.

Mr. Shan Baojie joined the Group in August 2021 as a non-executive Director and was re-designated as an executive Director in December 2021, and he is also the vice president of the Company. Mr. SHAN obtained a master degree in Accounting from Renmin University in June 2002 and a bachelor degree in Chemistry from Wuhan University in July 1992. Mr. SHAN is also currently the vice general manager of CR Healthcare, the Company’s controlling shareholder, and is also taking the office as a director of a number of its subsidiaries. Prior to joining CR Healthcare, Mr. SHAN was with the Group from 2011 to 2016 as the executive general manager and then the vice general manager, and he was also an executive Director of the Company from February 2016 to November 2016. He had served in a variety of roles at the State Food and Drug Administration from 1998 to 2011, and also completed a training program at the World Health Organization in 2007, where he gained experience in the U.S. pharmaceutical supervision and management system. From July 1992 to July 1998, Mr. SHAN worked in the general manager’s office of the Northeast Pharmaceutical Group Co., Ltd 

Ms. Yang Min was appointed as an executive Director and the Chief Financial Officer in June 2023. She is currently the chief financial officer of CR Healthcare. Previously, Ms. YANG served as the general manager of the finance department of China Resources Gas Group Limited, a company listed on the Stock Exchange (Stock Code: 1193) from December 2019 to May 2023, and she has successively served in various positions of the aforesaid company from November 2009 to December 2019 including senior deputy general manager of the finance department, deputy general manager of the audit department (acting head of department), deputy general manager of the finance department, assistant general manager of the finance department, senior manager of the finance department, assistant to the general manager and financial manager of its subsidiaries, and the expatriate responsible person of finance. Prior to that, Ms. YANG served successively as manager, senior auditor and auditor of Ernst & Young Huaming LLP Shenzhen Branch from September 2002 to November 2009. Ms. YANG holds a bachelor’s degree in management majoring in accounting from the School of Economics and Management of Northwestern University and is a Certified Public Accountant of the PRC. 

Ms. Ge Lu was appointed as a non-executive Director and a member of the Remuneration Committee in September 2023. She was appointed as a non-executive director of China Resources Gas Group Limited (stock code: 1193) in September 2023, an external director of China Resources Digital Holdings Co., Limited in November 2021 and an external director of CR Healthcare in August 2021. She is also a designated external director of the business unit(s) of China Resources Group. Ms. GE served as positions including the vice general manager, chief information officer of China Resources Pharmaceutical Commercial Group Limited (华润医药商业集团有限公司) and China Resources Pharmaceutical Group Limited (华润医药集团有限公司) and the general manager assistant of Beijing Pharmaceutical Co., Ltd. (北京医药股份有限公司) (now known as China Resources Pharmaceutical Commercial Group Limited (华润医药商业集团有限公司)) from January 2010 to August 2021. Ms. GE has over 30 years of working experience in the pharmaceutical industry and specializes in supply chain management, logistics management and information systems management and planning in the pharmaceutical distribution field. Ms. GE holds a master’s degree of business administration from Tsinghua University (清华大学) and a bachelor’s degree of computer science from Beijing Jiaotong University (北京交通大学), and holds the title of Senior Engineer.

Mr. Wu Ting Yuk, Anthony, joined the Group in August 2018 as an independent non-executive Director and the Chairman, and then resigned as the Chairman in April 2021. Mr. WU was appointed as the chairman of the Remuneration Committee in November 2022, and a member of the Nomination Committee in June 2023. Mr. WU is a leader in the healthcare industry and has extensive management experience in medical system. Mr. WU joined the board of the Hong Kong Hospital Authority in 1999 and was formerly its chairman from 2004 to 2013. He has so far been the longest serving chairman of the Hospital Authority. He has led the team of the Hospital Authority to manage all public hospitals and public clinics in Hong Kong and implemented the public health policy of the Hong Kong Government. He has also actively promoted a number of public and private medical co-operation projects during his tenure. Mr. WU is currently the principal advisor to the State Administration of Traditional Chinese Medicine of the PRC, a member of the Chinese Medicine Reform and Development Advisory Committee. He was a member of the State Council’s Medical Reform Leadership Advisory Committee and an advisor to the Public Policy Advisory Committee of the National Health and Family Planning Commission. Other important public positions that Mr. WU has served include a member of the 12th and 13th Standing Committee of the Chinese People’s Political Consultative Conference National Committee, and has been awarded JP and GBS by the government of Hong Kong. Mr. WU also served as the chairman of the Chamber Council of the Hong Kong General Chamber of Commerce from 2010 to 2012, and is currently a member of its consultation committee. He is currently a board member of the West Kowloon Cultural District Authority. Mr.  WU was a partner of Ernst & Young (“EY”) from 1985 to 2015, and served as chairman of the EY’s Far East Region from 2000 to 2005. He is currently the chief advisor to MUFG Bank, Ltd., the chairman of The China Oxford Scholarship Fund, an honorary professor of the Faculty of Medicine of the Chinese University of Hong Kong, the Faculty of Medicine of the Hong Kong Baptist University and the Peking Union Medical College Hospital, and an honorary fellow of the Hong Kong College of Community Medicine. Mr. WU also has directorships in certain listed companies of the main board of the Stock Exchange: he is an independent non-executive director of Sing Tao News Corporation Limited (stock code: 1105), Power Assets Holdings Limited (stock code: 6), Cstone Pharmaceuticals (stock code: 2616), Ocumension Therapeutics (stock code: 1477) and Hui Xian Real Estate Investment Trust (stock code: 87001), and is also the chairman and non-executive director of CLARITY MEDICAL GROUP HOLDING LIMITED (stock code: 1406), and the chairman and independent non-executive director of Venus Mecttech (Hangzhou) Inc. (stock code: 2500). He was an executive director of Sincere Watch (Hong Kong) Limited (stock code: 444); and an independent non-executive director of Guangdong Investment Limited (stock code: 270) and China Taiping Insurance Holdings Company Limited (stock code: 966). He was also an independent non-executive director of Agricultural Bank of China Limited (stock code: 1288) from 2009 to 2015. He was also a director of the Fidelity Funds from 2011 to 2014. Mr. WU is a fellow of the Hong Kong Institute of Certified Public Accountants and the Institute of Chartered Accountants in England and Wales, and the honorary chairman of the Institute of Certified Management Accountants (Australia) Hong Kong Branch. 

Mr. Fu Tingmei joined the Group in February 2023 as an independent non-executive Director and also a member of the Audit Committee and the Remuneration Committee, and was appointed as the chairman of the Audit Committee in June 19, 2025. He currently serves as an independent non-executive director of the following companies which are listed on the Stock Exchange: China Resources Pharmaceutical Group Limited (stock code: 3320), Guotai Junan International Holdings Limited (stock code: 1788), COFCO Joycome Foods Limited (stock code: 1610) and China Zheshang Bank Co., Ltd. (stock code: 2016; also listed on Shanghai Stock Exchange (stock code: 601916)). Mr. FU was an independent non-executive director of Beijing Enterprises Holdings Limited, a company listed on the Stock Exchange (stock code: 0392) from July 2008 to June 2017, an independent non-executive director of CPMC Holdings Limited, a company listed on the Stock Exchange (stock code: 0906) from June 2008 to July 2019 and an independent non-executive director of Postal Savings Bank of China Co., Ltd., a company listed on the Stock Exchange (stock code: 1658) from May 2016 to March 2023. Mr. FU has over 30 years of experience in investment, finance, law and business management. Mr. FU holds a master’s degree in law and a Ph.D. degree in law from London University, the United Kingdom. 

Mr. Zhou Peng was appointed as an independent non-executive Director and a member of the Audit Committee in September 2023. Mr. ZHOU was appointed as an executive director of HKE Holdings Limited (which is listed on the main board of the Stock Exchange, stock code: 1726) since August 2024. He is the founder of Deep Blue Ridge Capital (“DBR Capital”). DBR Capital is a multi-strategy investment firm based in Hong Kong. Mr. ZHOU has 20 years of experience in global mergers and acquisitions and capital markets. Before founding DBR Capital, Mr. ZHOU worked in Deutsche Bank (Hong Kong) and Credit Suisse (New York), and cooperated with the world’s top institutional and corporate clients to complete a number of cross-industry and cross-product transactions; and Mr. ZHOU’s career began in Bank of China. Mr. ZHOU holds a master’s degree in business administration from Columbia University in New York. 

Ms. Lo Wing Sze BBS, JP, was appointed as an independent non-executive director and member of the Audit Committee and the Nominating Committee. Ms. LO holds a Bachelor of Economics Degree from the University of Sydney and a Master of Commerce in Finance Degree from the University of New South Wales in Australia. She is a member of the Hong Kong Institute of Certified Public Accountants and a fellow member of CPA Australia. Ms. LO is the financial director of Million Group, and has 25 years of experience in corporate governance, tourist services and hotel management. Ms. LO joined the group on 19 June, 2025.

Ms. LO is a member of the Election Committee 2021 (The Fourth Sector) of the Hong Kong Special Administrative Region (“HKSAR”) and was a member of the Election Committee for the Fifth Government of the HKSAR (Tourism Subsector). She is an AllChina Women’s Federation HKSAR delegate.

Ms. LO is a member of the Chief Executive’s Policy Unit Expert Group, the Advisory Committee on Post-office Employment for Former Chief Executives and Politically Appointed Officials, the Advisory Committee on Admission of Quality Migrants and Professionals, the Immigration Department Users’ Committee, the Correctional Services Children’s Education Trust Investment Advisory Board and the District Fight Crime Committee (Wan Chai District). She is also an Honorary Court Member of the Lingnan University. Ms. LO is the chairlady of Tai Hang Five Dragon Heritage Centre (Revitalising Historic Buildings Through Partnership Scheme Batch IV), a founding member of Hong Kong Red Cross EmpowerHer Network and a member of the Hong Kong Society of Rehabilitation Fundraising and Social Enterprise Committee.

Ms. LO is currently an independent non-executive director of China Resources Mixc Lifestyle Services Limited (stock code: 1209), New World Development Company Limited (stock code: 17), Goldlion Holdings Limited (stock code: 533) and Lee & Man Paper Manufacturing Limited (stock code: 2314), all being companies listed on the Stock Exchange. She served as an independent non-executive director of Finsoft Financial Investment Holdings Limited (a company listed on the Stock Exchange, stock code: 8018) from August 2020 to July 2023, and an independent non-executive director of Virtual Mind Holding Company Limited (a company listed on the Stock Exchange, stock code: 1520) from January 2021 to June 2025.